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Cisplatin (cis-diamminedichloroplatinum) was first introduced
into clinical practice in 1971 and has now been licensed for use in
the treatment of cancer for over 20 years. Despite the continued
search for new platinum complexes and cisplatin analogues with
increased efficacy over the parent compound, cisplatin remains the
mainstay of treatment for a number of solid tumour types.
Cisplatin is currently an essential component in many clinical
paediatric protocols for the treatment of osteogenic sarcoma,
neuroblastoma and central nervous system tumours (Bramwell
et al, 1992; Pearson et al, 1992; Buckner et al, 1999). In addition,
cisplatin has a pivotal role in the foundation of curative regimens
in ovarian and testicular cancers and is also effective in the treat-
ment of bladder, cervical, oesophageal and small cell lung cancers,
amongst others. 
The clinical application of cisplatin is predominantly limited by
the considerable side effects of cisplatin treatment, which include
acute toxicity such as nausea and vomiting and chronic side effects
of nephrotoxicity, ototoxicity and neurotoxicity (Krakoff, 1979;
Vermorken et al, 1983; Cavaletti et al, 1992). While the search for
superior platinum drugs continues, it is essential that methods are
investigated to optimize the current clinical use of cisplatin in both
paediatric and adult patient populations. Although a variety of
different approaches have been undertaken to limit its side effects,
none have proven wholly successful in reducing either the acute or
chronic toxicities associated with cisplatin therapy. 
Recent studies have shown that encapsulation of antineoplastic
agents in liposomes can maintain antitumour activity whilst
reducing drug toxicity (Rahman et al, 1990; Gill et al, 1995).
Using this approach it is feasible that high plasma levels of free
cisplatin, which are associated with the side effects of the drug,
may be reduced whilst at the same time allowing more specific
targeting of cisplatin to the tumour. This type of liposome delivery
system has previously been used successfully for the delivery of
doxorubicin in both animal and patient studies (Papahadjopoulous
et al, 1991; Vaage et al, 1992; Uziely et al, 1995; Muggia et al,
1997). 
SPI-77 (STEALTH® liposomal cisplatin) is a formulation of
cisplatin encapsulated in sterically stabilized liposomes. These
liposomes are thought to accumulate in tumours following
extravasation through the tumour vasculature, due to their small
size, long circulation time and reduced interaction with compo-
nents of the blood including lipoproteins, cells, opsonins and other
liposomes (Woodle and Lasic, 1992). Preclinical studies in
tumour-bearing mice showed SPI-77 to have superior antitumour
activity compared to the same cumulative dose of cisplatin with
higher cumulative doses of SPI-77 being well tolerated and
exhibiting increased antitumour affect (Newman et al, 1999).
Significantly, SPI-77-treated animals had a 28-fold higher tumour
A phase I study in paediatric patients to evaluate the
safety and pharmacokinetics of SPI-77, a liposome
encapsulated formulation of cisplatin 
GJ Veal1, MJ Griffin1, E Price2, A Parry2, GS Dick3, MA Little3, SM Yule4, B Morland5, EJ Estlin6, JP Hale2, 
ADJ Pearson2, H Welbank7 and AV Boddy1
1Cancer Research Unit and 2Department of Child Health, Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne NE2 4HH, UK; 3Royal
Marsden Hospital, Sutton, Surrey SM2 5PT, UK; 4Yorkhill Hospital, Glasgow G3 8SJ, UK; 5Birmingham Childrens Hospital, Birmingham B4 6NH, UK; 6Royal
Hospital for Sick Children, Bristol BS2 8BJ, UK; 7ALZA Corporation, Mountain View, CA, USA 
Summary Pre-clinical studies indicate that cisplatin encapsulated in STEALTH® liposomes (SPI-77) retains anti-tumour activity, but has a
much reduced toxicity, compared to native cisplatin. A phase I study was conducted to determine the toxicity and pharmacokinetics of SPI-77
administered to children with advanced cancer not amenable to other treatment. Paediatric patients were treated at doses ranging from 40 to
320 mg m–2 by intravenous infusion every 4 weeks. Blood samples taken during, and up to 3 weeks after, administration and plasma and
ultrafiltrate were prepared immediately. Urine was collected, when possible, for 3 days after administration. SPI-77 administration was well
tolerated with the major toxicity being an infusion reaction which responded to modification of the initial infusion rate of SPI-77. Limited
haematological toxicity and no nephrotoxicity were observed. No responses to treatment were seen during the course of this phase I study.
Measurement of total plasma platinum showed that cisplatin was retained in the circulation with a half life of up to 134 h, with maximum
plasma concentrations approximately 100-fold higher than those reported following comparable doses of cisplatin. Comparison of plasma and
whole blood indicated that cisplatin was retained in the liposomes and there was no free platinum measurable in the ultrafiltrate. Urine
recovery was less than 4% of the dose administered over 72 h. Results from this phase I study indicate that high doses of liposomal cisplatin
can safely be given to patients, but further studies are required to address the issue of reformulation of liposomally bound cisplatin. © 2001
Cancer Research Campaign http://www.bjcancer.com
Keywords: SPI-77; liposomal cisplatin; pharmacokinetics; paediatrics; phase I 
1029
Received 11 August 2000 
Revised 11 November 2000 
Accepted 22 January 2001 
Correspondence to: AV Boddy 
British Journal of Cancer (2001) 84(8), 1029–1035
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1723, available online at http://www.idealibrary.com on  http://www.bjcancer.comexposure to platinum, as determined by area-under-the-curve
(AUC), than cisplatin-treated animals, but a 4-fold lower exposure
of platinum to the kidneys, which represents the primary target
organ of toxicity associated with cisplatin treatment. 
A phase I study of SPI-77 in children in the UK was conducted
in parallel to the adult phase I study in the UK and Europe. This
study was designed to determine the incidence of toxicity,
maximum tolerated dose (MTD) and pharmacokinetics of SPI-77
when given every 4 weeks in paediatric patients with advanced
cancer not amenable to other treatment. 
PATIENTS AND METHODS 
Patients 
The study was performed between October 1997 and March 1999.
Patients with different tumour types (Table 1) were recruited from
4 centres in the United Kingdom. Patients eligible for the study
were aged 1–17 years with histologically confirmed malignancy
for which no conventional therapy offered the possibility of cure
or palliation. Previous chemotherapy must have ceased 4 weeks
prior to recruitment to the study (6 weeks for nitrosourea) and 4
weeks must have elapsed since either cancer surgery or radio-
therapy to measurable lesions. Further inclusion criteria were a
Lansky performance status ³ 30%, an adequate bone marrow func-
tion (absolute neutrophil count ³ 1.0 ´ 109 l–1, platelet count ³100
´ 109 l–1), an adequate liver function (total bilirubin level within
upper limit of normal, alanine aminotransferase and aspartate
aminotransferase  ≤ 1.5 upper limit of normal), an adequate renal
function (glomerular filtration rate (GFR) > 50 ml min–1 1.73 m–2)
and no clinical evidence of hearing loss determined by audiometry
(i.e., no toxicity ³ grade 2 Common Toxicity Criteria (CTC)).
Written informed consent was obtained from the patient’s parent
or legal guardian and consent was also sought from the patient
where deemed appropriate. 
Excluded from the study were patients with a life expectancy of
less than 6 weeks, signs or symptoms of acute infection requiring
systemic therapy, neurotoxicity from previous anti-cancer treat-
ment or significant neuropathy (> grade 1 CTC) from any cause.
Further exclusion criteria were a history of allergic reaction 
to cisplatin- or platinum-containing compounds, use of another
investigational agent within 30 days of dosing with SPI-77 or prior
treatment with SPI-77. 
Pretreatment evaluation consisted of radiologic assessment of
disease, ECG and audiogram within 14 days prior to the first
dose of SPI-77. Further evaluation included a full medical
history, physical examination, neurologic examination, an esti-
mate of the GFR by 51Cr-EDTA plasma clearance, urine analysis,
haematology including WBC with differential, red blood cell,
haemoglobin, haematocrit and platelet count, and serum chem-
istry, glucose and a lipid profile. A urine pregnancy test was also
carried out in female patients of childbearing potential. The
study was approved by the appropriate Local Research Ethics
Committee (LREC).
Drug formulation 
SPI-77 was supplied by SEQUUS Pharmaceuticals, Inc
(Brentford, UK) in single-dose sterile vials as an isotonic suspen-
sion containing a cisplatin concentration of 1 mg ml–1. The
total lipid content of the SPI-77 formulation was 71 mg ml–1
(hydrogenated soy phosphatidylcholine, cholesterol and the
polymer MPEG-DSPE at an approximate 51:44:5 molar ratio),
giving a drug-to-lipid ratio of approximately 14 mg cisplatin per
1 mg of lipid. The formulation also contained 10% sucrose, 1 mM
sodium chloride and 10 mM histidine at pH 6.5. The mean lipo-
some particle diameter was 110 nm and the cisplatin encapsulation
exceeded 90%. Prior to infusion, SPI-77 was diluted to a final
concentration of 0.2 mg ml–1 in normal saline or D5W (dextrose
5% in water). All doses of SPI-77 quoted in this study are given in
cisplatin equivalents of mg m–2. 
Treatment plan 
Patients received SPI-77 every 4 weeks for a total of 6 doses or
until disease progression, whichever occurred earlier. 3 patients
were initially enrolled for each dose level. SPI-77 was adminis-
tered by intravenous (i.v.) infusion at a rate of 10 mg m–2 h–1 for the
first 15 minutes, which increased to 40 mg m–2h–1 for the
remainder of the infusion, assuming no adverse reaction had
occurred. All SPI-77 infusions were administered using a paedi-
atric approved infusion pump. All patients received premedication
with dexamethasone (0.15 mg kg–1 qds oral or i.v.), chlorpheni-
ramine (0.05 mg kg–1 qds oral or i.v.) and ranitidine (3 mg kg–1 bd
oral or 1 mg kg–1 i.v. tds) starting 24 h prior to SPI-77 infusion and
continuing for 24 h after the infusion. The starting dose of SPI-77
was 40 mg m–2 for the first 3 patients with planned dose escala-
tions as follows: 80, 120, 200, 320, 520, 840 mg m–2, provided that
no dose-limiting toxicities were observed. The last patient at each
dose level was observed for at least 4 weeks before the first patient
at the subsequent dose level was treated. If a dose-limiting toxicity
(DLT) occurred in one of 3 patients at any given dose level, then 3
additional patients were treated at that level. The maximum toler-
ated dose (MTD) was defined as the dose immediately below that
at which 2 out of 6 patients experienced a DLT. 
DLT was defined as NCI CTC grade 3 thrombocytopenia or
neutropenia lasting more than 7 days, grade 3 hepatic toxicity
which does not resolve at least to grade 1 prior to the end of the
cycle or any grade 3 or higher neurological or kidney/bladder toxi-
city. Any other grade 3 or 4 event, with the exception of nausea,
vomiting, alopecia, weight change, fatigue and allergic reactions
was also considered dose limiting. 
Clinical evaluations 
During each 4 week cycle of SPI-77 treatment, haematology and
serum chemistry and electrolytes were checked on a weekly basis.
Urine analysis and neurologic examination were performed at the
end of each cycle and an audiogram and GFR measurement
carried out by 51Cr-EDTA plasma clearance at the end of cycles 2,
4 and 6. Upon completion of treatment, an electrocardiogram was
also performed. Tumour evaluation and assessment of response
was carried out at the end of cycles 2, 4 and 6 or at early with-
drawal for patients not completing the entire course of treatment. 
Pharmacokinetic sampling 
During the first course of treatment, whole blood samples (approx.
3 ml) were collected in heparinized tubes prior to administration of
SPI-77, hourly during infusion and at the end of infusion. Further
samples were taken at 1, 3, 5, 24, 96, 120 and 168 hours post infu-
sion and weekly thereafter for 2 additional weeks. For subsequent
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hourly during infusion and at the end of infusion. A 400 ml aliquot
of blood was removed from each sample and the remainder
centrifuged for 10 minutes at 4˚C (2000 g) to obtain the plasma
fraction. Whole blood and plasma samples (400 ml) were diluted
10-fold with 0.1% triton-X-100 +0.2% nitric acid to a final volume
of 4 ml. These samples were stored at –20˚C prior to analysis. The
remaining plasma was centrifuged for 30 minutes at 1500 g using
Amicon Centrifree ultrafiltration devices to obtain a minimum of
200 ml of plasma ultrafiltrate and the samples stored at –20˚C prior
to analysis. 
Urine samples were collected, where possible, beginning on the
first day of treatment with the initiation of dosing and continuing
each day for 3 consecutive days. 24 h pooled urine volumes were
recorded and 10 ml of each pooled urine sample stored for analysis
along with a 10 ml predose spot urine sample. 
All platinum analyses were carried out at the Cancer Research
Unit, Newcastle, by flameless atomic absorption spectrophotom-
etry using a Perkin-Elmer AAnalyst 600 graphite furnace spec-
trometer (Perkin-Elmer Ltd, Beaconsfield, UK). Sample analysis
was carried out using a 4-stage heating programme with tempera-
tures ramping from 80 to 2800˚C. Total platinum concentrations
were determined in whole blood and plasma samples and free 
platinum levels determined in plasma ultrafiltrates (Peng et al,
1997). All samples were analysed in duplicate and the intra- and
interassay coefficients of variation for a quality assurance sample
had to be <10% for an assay to be valid. The limit of detection for
the AAS was 0.10 mg ml–1. 
Data interpretation 
The total and free platinum pharmacokinetic parameters in plasma
and urine were calculated by standard non-compartmental analysis
with actual sampling times used in the calculations. Analysis of all
pharmacokinetic data was performed using WinNonlin. 
RESULTS 
Patients and treatment 
A total of 18 patients were recruited to the study. Patient character-
istics are shown in Table 1. 3 patients were treated at the starting
dose of 40 mg m–2 (4 courses in total) and 4 patients were treated at
80 mg m–2 (4 courses) due to the withdrawal of 1 patient following
a grade 3 infusion reaction. 3 patients were treated at 120 mg m–2 (6
courses), 4 patients at 200 mg m–2 (6 courses) and 3 patients at 320
mg m–2 (5 courses) giving a total of 25 courses administered
overall. 10 patients received a single course of treatment, 4 patients
received 2 courses (at doses of 40, 80, 120 and 320 mg m–2) and 
2 patients received 3 courses (doses of 120 and 200 mg m–2). No
further dose escalations were carried out due to concerns regarding
the high doses of cisplatin being administered to patients in both
the adult (Schellens et al, 1998) and paediatric phase I studies 
and the lack of detectable levels of free platinum measured in
patient ultrafiltrate samples, indicating that the cisplatin was being
retained within the liposomes. Following the occurrence of infu-
sion reactions in 3 patients receiving doses of SPI-77 of 40 and 
80 mg m–2, in addition to similar adverse infusion-related reactions
in the parallel phase I adult study, the initial infusion rate was
decreased to 1 mg m–2 h–1 for the first 15 minutes, followed by a step
increase up to 40 mg m–2 h–1 for the remainder of the infusion, giving
an increased duration of infusion at doses of 120 mg m–2 and above.
Due to this increased duration of infusion, the final concentration of
SPI-77 was increased from 0.2 mg ml–1 to 0.3 mg ml–1, in order to
maintain the total infusion volumes at acceptable levels. 
Of the 18 patients recruited to the study, 1 patient did not receive
SPI-77 due to disease progression prior to treatment, 1 patient was
withdrawn following a serious infusion reaction and 3 patients
died after the first course of therapy due to disease progression. No
responses to treatment were observed in any of the patients
studied. The remaining 13 patients went off-study following 1 (6
patients), 2 (5 patients) and 3 (2 patients) courses of SPI-77 treat-
ment due to disease progression. Of the 5 patients who received 2
courses of treatment, 3 had rhabdomyosarcoma, 1 neuroblastoma
and 1 PNET. Of the 2 patients who received 3 courses, 1 had hepa-
tocellular carcinoma and the other neuroblastoma. 
Toxicity 
17 patients were evaluable for toxicity. Table 2 shows a summary
of all the toxicities above CTC grade 1 recorded during this study.
The most serious adverse event was a CTC grade 3 infusion reac-
tion observed in 3 patients at doses of 40 and 80 mg m–2 during the
first course of treatment in each case. This led to 1 patient being
withdrawn from the study and resulted in modification of the
initial infusion rate of SPI-77 for further dose escalation as
described above. The other 2 patients were able to recommence
administration on the same day, following resolution of the symp-
toms and treatment with antihistamines, steroids and oxygen. No
subsequent infusion reactions were seen in patients treated under
the reviewed guidelines for initial SPI-77 infusion. Gastroin-
testinal toxicities were the most commonly observed in children
receiving SPI-77, with a total of 65% of patients (11/17) experi-
encing vomiting during the course of treatment and a further 18%
of patients (3/17) experiencing nausea. Neither of these toxicities
exceeded CTC grade 2 in any of the patients studied. 1 patient
experienced a CTC grade 4 GI bleed, but this was not thought to be
treatment related. Haematological toxicity was limited to grade 2/3
anaemia in 35% of patients (6/17) and grade 2 thrombocytopenia
in 12% of patients (2/17). In 1 of these patients bone marrow
disease is likely to have compromised platelet levels. Other toxici-
ties observed included grade 3 hypertension (1/17), grade 1 fever
(3/17), grade 1/2 allergic reaction (4/17) and grade 1 hyponatrenia
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Table 1 Patient characteristics 
Number of patients 18 
Male/female 10/8 
Median age (range) 10 (1–16) 
Dose level (number of courses) 
40 mg m–2 3 (4) 
80 mg m–2 4 (4) 
120 mg m–2 3 (6) 
200 mg m–2 4 (6) 
320 mg m–2 3 (5) 
Diagnosis 
Neuroblastoma 5 
Rhabdomyosarcoma 5 
PNET (intra/extracranial) 2 (1/1) 
Astrocytoma 1 
Hepatocellular carcinoma 1 
Ewings sarcoma 1 
Small cell osteosarcoma 1 
Medulloblastoma 1 (2/17). Altered serum chemistry/electrolytes such as hypo-
kalaemia, hyperbilirubinaemia and decreased phosphate were
never greater than grade 1 and were never reported in more than
6% of patients (1/17). 
Monitoring of blood lipids 
Levels of cholesterol, HDL and LDL fractions and triglycerides
were monitored during treatment with SPI-77 due to the high lipid
content of the STEALTH® liposomes being administered. Peak
cholesterol levels were observed at 8 days following administra-
tion of SPI-77 and then declined to levels approximating those
seen prior to treatment by day 29. The relationship between dose
of SPI-77 and corresponding increase in cholesterol levels is
shown in Figure 1. Percentage increases in mean cholesterol levels
at 8 days following SPI-77 administration were 77%, 102% and
244% at doses of 120, 200 and 320 mg m–2 respectively. Similar
increases were seen in levels of HDL and LDL, for example at a
SPI-77 dose of 320 mg m–2. Mean percentage increases from
pretreatment levels of HDL and LDL measured at 8 days were
300% and 143% respectively. Variations in triglyceride levels
were less clearly defined, but increased levels were seen in the
majority of patients over a 28 day period following treatment with
SPI-77. 
Pharmacokinetics 
Blood samples were taken for analysis of platinum during infusion
of SPI-77 and for up to 3 weeks after administration. These plat-
inum concentration data were used to derive pharmacokinetic
parameters for total platinum in plasma and whole blood. Full
pharmacokinetic data were obtained for 12 patients and are shown
in Table 3. Despite the high concentrations of cisplatin adminis-
tered to patients in this study, concentrations of free platinum
measured in the plasma ultrafiltrate remained below the limit of
detection (0.10 mg ml–1) throughout the treatment period. Cisplatin
was detectable in plasma and whole blood after SPI-77 administra-
tion in all patients. Individual patient plasma time profiles repre-
sentative of the dose levels studied are shown in Figure 2. At the
highest dose level, plasma platinum concentrations were still
measurable prior to administration of the second course of treat-
ment, i.e. 4 weeks after drug infusion. A plot of total platinum area
under the plasma concentration–time curve (AUC) versus the dose
of SPI-77 is shown in Figure 3. The half-life values for total plat-
inum in plasma, determined following SPI-77 treatment, were
within the range of 38 to 134 h in all but 1 patient, indicating an
approximate 3-fold variation. Distribution of cisplatin within
whole blood was determined by the blood/plasma ratio and ranged
from approximately 0.5–0.8 in the majority of patients studied
(Table 3), this generally reflected the haematocrit in these patients.
The pharmacokinetic profile of patient 2 was notably different
from that of the other patients studied, with a significantly greater
clearance, reduced AUC and half-life and a blood/plasma 
ratio approaching 1. Patient 8 received multiple blood transfusions
within 72 hours of SPI-77 administration, which resulted in an
increased rate of elimination and disruption of whole blood 
distribution (Figure 4). Urine data was obtained from 6 patients
and indicated prolonged and limited excretion, with a value of 
3.8 ± 0.9% (mean ± SD) of the dose excreted in the first 
72 hours. 
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Table 2 Patient toxicities 
Toxicity Grade Number of patients (%) Number of courses (%) 
Gastrointestinal 
Vomiting 1.2 11 (64) 13 (52) 
Nausea 1.2 4 (24) 4 (16) 
GI bleed 4a 1 (6) 1 (4) 
Haematologic 
Anaemia 2 4 (24) 5 (20) 
3b 2 (12) 3 (12) 
Thrombocytopenia 2 2 (12) 2 (8) 
Infusion reaction 3c 3 (18) 3 (12) 
Dermatologic 
Allergy/rash 1.2 4 (24) 4 (16) 
Alopecia 1 1 (6) 1 (4) 
Other toxicities 
Fever 1 3 (18) 3 (12) 
Hypertension 3d 1 (6) 1 (4) 
aDose level 120 mg m–2; bDose levels 40 and 120 mg m–2; cDose levels 40 and 80 mg m–2; dDose
level 80 mg m–2. 
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Figure 1 Mean plasma levels of total cholesterol following SPI-77
administration at doses of 40 to 320 mg m– 2 following the first course of
treatment. Error bars indicate standard error of the mean DISCUSSION 
The potential use of liposomes to deliver drugs to target sites of
disease is a therapeutic approach that has been investigated with
many different agents over the past 2 decades. Recent successes in
this area of clinical research include the efficacy of liposomal
doxorubicin in AIDS-related Kaposi’s sarcoma and patients with
refractory ovarian cancer (Muggia et al, 1997; Northfelt et al,
1997). Although the precise mechanisms by which liposomes
selectively enter tumours and release drug are not completely
understood, their successful application with doxorubicin has led
to a resurgence of interest in this area. As liposome formulation
issues and potential problems such as liposome stability and
removal by elements of the immune system have been overcome
with the STEALTH® liposomal system, the potential exists for
improved delivery of a growing number of drugs for the treatment
of many different types of disease. In addition, results from
previous clinical trials give an indication as to how patients are
likely to respond to the administration of STEALTH® liposomes
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Table 3 Pharmacokinetics of total platinum in plasma following SPI-77 treatment 
Patient Dose Infusion  Cmax AUC Cl  t1/2 Blood/plasmaa
(mg m–2) time (h) (mg ml–1) (mg ml–1 min) (ml h–1) (h)
1 40 2 34 145 20 38 0.72–0.88 
2 40 4 8 4 255 11 0.69–1.00 
3 40 5 37 181 17 65 0.54–0.66 
5 80 3 71 402 5 56 0.49–0.80 
7 80 5 103 818 13 134 0.60–0.88 
8 120 4 88 442 18 41 0.31–0.79 
9 120 3 111 679 19 86 0.57–0.85 
10 120 4 151 1359 7 96 0.30–0.68 
12 200 6 142 1412 9 78 0.55–0.76 
13 200 6 177 1788 4 82 0.53–0.75 
16 320 7 411 8027 2 132 0.54–0.73 
18 320 6 187 2157 8 73 0.74–1.05 
aBlood/plasma ratio given as a range determined over the 3 week sampling period. 
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Figure 3 Relationship between total platinum area under the plasma
concentration–time curve (AUC) and the dose of SPI-77 administered 
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Figure 4 Concentrations of total platinum in plasma and whole blood
following SPI-77 administration at a dose of 120 mg m–2 following the first
course of treatment for patient 8. Patient received multiple blood transfusions
within 72 h of SPI-77 administration and the potential toxicities that may be associated with their use.
Therefore the main issue regarding their use for the delivery of
other therapeutic agents will largely be concerned with obtaining
the desired balance between encapsulation and release of the drug
of interest. 
Preclinical results with SPI-77, a formulation of cisplatin encap-
sulated in STEALTH® liposomes, showed promising results in
comparison with native cisplatin. Data from tumour-bearing
mouse models showed a significantly greater antitumour activity
compared to cisplatin and a significantly increased tumour
exposure to platinum. This coincided with a decreased platinum
exposure to the kidneys, the principal organ of cisplatin toxicity
(Newman et al, 1999). On the basis of these preclinical results, in
addition to the previous success of STEALTH® liposomal doxoru-
bicin, phase I studies in both adult and paediatric patients, with
advanced cancer not amenable to other cancer treatments, were
performed in the UK and Europe. These studies were designed to
determine the incidence of toxicity, MTD and pharmacokinetics of
SPI-77 in these 2 separate patient populations. The rate of patient
recruitment to the 2 studies was such that the adult phase I study
was always one dose level ahead of the paediatric study, i.e. chil-
dren were not enrolled for the next dose level until the specified
number of adult patients had been treated at that dose. 
Complete pharmacokinetic profiles were obtained from 12 of
the patients taking part in this study. Cisplatin levels were deter-
mined in 2 different forms, total cisplatin concentrations were
determined in both patient plasma and whole blood samples and
concentrations of free platinum were determined in plasma ultra-
filtrate samples. The cisplatin blood/plasma concentration ratio
following SPI-77 treatment reflected the haematocrit in most
patients. This contrasts with the equal distribution of platinum
between plasma and red cells following native cisplatin adminis-
tration (Manaka and Wolf, 1978). This information, in combina-
tion with the fact that there was no measurable free/active drug in
plasma ultrafiltrate samples strongly suggests that the drug was
retained within the liposomes following administration. 
Plasma concentrations of total platinum following treatment
with SPI-77 were considerably higher than those reported
following administration of native cisplatin in children (Bues-
Charbit et al, 1987; Dominici et al, 1989). For example, the total
platinum AUC values obtained at a SPI-77 dose of 80 mg  m–2 in
this phase I study were approximately 100-fold higher than the
total platinum AUC values previously reported following an
equivalent dose of cisplatin (Pratt et al, 1981). This marked
increase in total platinum AUC can largely be explained by the
apparent decrease in clearance of total platinum and the low
percentage of total platinum dose excreted in the urine of patients
following SPI-77 administration. Total platinum clearance values
observed for SPI-77 in the current study were ≤20 ml h–1 in all but
1 patient, approximately 100- to 1000-fold lower than clearance
values of 10–20 l  h–1 m–2 commonly reported for cisplatin (Bues-
Charbit et al, 1987; Peng et al, 1997). Similarly, the limited excre-
tion of cisplatin in the urine of children observed following SPI-77
administration, with approximately 4% of the administered dose
excreted in the first 72 hours, was significantly less than seen with
native cisplatin, with reported values of 27–35% of the dose
excreted in 48 hours (Bues-Charbit et al, 1987; Peng et al, 1997).
Overall, the half-life of cisplatin was prolonged following SPI-77
administration, but was not dissimilar to that of total plasma plat-
inum reported following cisplatin administration in previous clin-
ical studies (Pratt et al, 1981; Dominici et al, 1989). There was
some evidence of non-linearity, with lower clearance and longer
half-life of drug at the higher dose levels. This was also apparent
from individual patient plasma time profiles representative of the
dose levels studied (Figure 2). 
One patient (patient 2) showed a different pharmacokinetic
profile to the other patients with a blood/plasma ratio approaching
unity and a much shorter half-life due to a higher clearance of
cisplatin. As the data suggest that the drug was normally retained
in the liposomes following administration of SPI-77, it seems
likely that the different pharmacokinetics observed in this patient
was due to altered handling of the liposomes. This may involve a
decrease in liposome stability through interaction with plasma
proteins or an increased clearance of liposome from the plasma. It
is interesting to note that no increase in cholesterol levels was seen
at 8 days after infusion of SPI-77 in this patient as compared to
increases of 7 and 46% from pretreatment levels in the other 2
patients treated at the same dose level. The only other patient who
exhibited a significantly different pharmacokinetic profile was
patient 8 who received multiple blood transfusions within 72 hours
of SPI-77 administration. This resulted in an increased rate of
elimination and disruption of whole blood distribution (Figure 4). 
The most striking clinical or biochemical observation was
hyperlipidaemia with percentage increases in mean cholesterol
levels at 8 days following administration being 77%, 102% and
244% at doses of 120, 200 and 320 mg m–2 respectively. Similar
increases were seen in levels of HDL and LDL. Despite the fact
that cholesterol levels returned to normal before the scheduled
retreatment time, the apparent exaggeration of this adverse effect
seen at a SPI-77 dose of 320 mg m–2 raises potential concerns with
regards to further dose escalation. Other toxicities, including
antiproliferative effects, were generally mild (CTC grade 1/2) with
the only serious adverse event being a GI bleed which was not
thought to be treatment related, due to a lack of related side effects
and the length of time after administration that the toxicity
occurred. Overall, administration of SPI-77 was well tolerated in
paediatric patients with doses 3-fold higher than would be achiev-
able with native cisplatin. However, despite this increase in
cisplatin dosage and the high levels of total platinum in plasma, no
responses were seen in any of the patients studied. 
In summary, the data from this study indicate that the encapsu-
lation of cisplatin in STEALTH® liposomes results in an altered
toxicity profile and significantly different pharmacokinetics as
compared with standard cisplatin administration in paediatric
patients. This is in agreement with preliminary data obtained in a
parallel phase I study of SPI-77 in adults (Schellens et al, 1998).
The absence of nephrotoxicity following treatment with SPI-77
may be explained predominantly by the lack of detectable free
platinum in the plasma, but may also be connected with the signi-
ficantly decreased percentage of platinum excreted in the urine
compared with cisplatin treatment. The major abnormal finding in
the study was hypercholesterolaemia with low-grade anaemia 
and thrombocytopenia being the only observed antiproliferative
effects. The pharmacokinetics of SPI-77 were significantly altered
from those associated with cisplatin treatment and implied that the
cisplatin was maintained inside the liposome with no detectable
free cisplatin measured in plasma at any point following adminis-
tration. Although preclinical data suggested that low plasma levels
of free cisplatin would explain the lack of toxicity seen with SPI-
77 in murine tumour models, the complete retention of cisplatin
within the liposomes was not predicted as significant antitumour
activity was observed (Newman et al, 1999). Both the paediatric
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order to address the issue of reformulation of liposomally bound
cisplatin, i.e. to attempt to obtain an optimal balance between
encapsulation and release of cisplatin. Despite the potential prob-
lems with formulation of liposomally bound cisplatin highlighted
in this study, the limited toxicity reported in patients in the study
does show that high doses of liposomal cisplatin can safely be
given to patients. This would suggest that if the product can be
reformulated to obtain the desired balance between encapsulation
and release, this approach has the potential to lead to an improved
method of administering cisplatin in a clinical setting. 
REFERENCES 
Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA,
Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der
Eijken J, Thomas D, Uscinska B, Machin D and van Glabbeke M (1992) A
comparison of two short intensive adjuvant chemotherapy regimens in operable
osteosarcoma of the limbs in children and young adults: the first study of the
European Osteosarcoma Intergroup. J Clin Oncol 10: 1579–1531 
Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel
DW, Raffel C, OFallon JR, Neglia J and Shaw EG (1999) Phase II trial of
primary chemotherapy followed by reduced-dose radiation for CNS germ cell
tumors. J Clin Oncol 17: 933–940 
Bues-Charbit M, Gentet JC, Bernard JL, Breant V, Cano JP and Raybaud C 
(1987) Continuous infusion of high-dose cisplatin in children:
pharmacokinetics of free and total platinum. Eur J Cancer Clin Oncol 23:
1649–1652 
Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR 
and Tredici G (1992) Cisplatin-induced peripheral neurotoxicity is 
dependent on total dose-intensity and single dose-intensity. Cancer 69:
203–207 
Dominici C, Petrucci F, Caroli S, Alimonti A, Clerico A and Castello MA (1989) A
pharmacokinetic study of high-dose continuous infusion cisplatin in children
with solid tumors. J Clin Oncol 7: 100–107 
Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA,
Forssen E, Ross ME and Levine AM (1995) Phase I/II clinical and
pharmacological evaluation of liposomal daunorubicin. J Clin Oncol 13:
996–1003 
Krakoff IH (1979) Nephrotoxicity of cis-dichlorodiammineplatinum (II). Cancer
Treat Rep 63: 1523–1525 
Manaka RC and Wolf W (1978) Distribution of cis-platin in blood. Chem Biol
Interactions 22: 353–358 
Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L,
Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso
LJ and Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory
ovarian cancer: antitumor activity and toxicity modification by liposomal
encapsulation. J Clin Oncol 15: 987–993 
Newman MS, Colbern GT, Working PK, Engbers C and Amantia MA (1999)
Comparative pharmacokinetics, tissue distribution, and therapeutic
effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes
(SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43: 1–7 
Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, 
Rios A, Krown SE, DuMond C and Mamelok RD (1997) Efficacy of
pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s
sarcoma after failure of standard chemotherapy. J Clin Oncol 15: 653–659 
Papahadjopoulous D, Allen TN, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee
KD, Woodle MC, Lasic DD, Redemann C and Martin FJ (1991) Sterically
stabilized liposomes: Improvement in pharmacokinetics and antitumor
therapeutic efficacy. Proc Natl Acad Sci (USA) 88: 11460–11464 
Pearson AD, Craft AW, Pinkerton CR, Meller ST and Reid MM (1992) High-dose
rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer
28A: 1654–1659 
Peng B, English M, Boddy AV, Price L, Wyllie R, Pearson ADJ, Tilby MJ and
Newell DR (1997) Cisplatin pharmacokinetics in children. Eur J Cancer 33:
1823–1828 
Pratt CB, Hayes A, Green AA, Evans WE, Senzer N, Howarth CB, Ransom JL
and Crom W (1981) Pharmacokinetic evaluation of cisplatin in children 
with malignant solid tumors: a phase II study. Cancer Treat Rep 65: 
1021–1026 
Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D and Woolley PV
(1990) A phase I clinical trial and pharmacokinetic evaluation of liposome
encapsualted doxorubicin. J Clin Oncol 8: 1093–1100 
Schellens JHM, Meerum Terwogt J, Groenewegen G, Blijham GH, Ten Bokkel
Huinink WW, Smart M, Maliepaard M. Floot B, Welbank H and Beijnen JH
(1998) Phase I and pharmacologic study of SPI-77, a novel stealth liposomal
encapsulated formulation of cisplatin (CDDP). Eighty-ninth annual meeting,
Proceedings American Association Cancer Research 39: P2218 
Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E,
Muggia FM and Gabizon A (1995) Liposomal doxorubicin (Dox-SL™):
Antitumor activity and unique toxicities during two complementary phase I
studies. J Clin Oncol 13: 1777–1785 
Vaage J, Mayhew E, Lasic D and Martin F (1992) Therapy of primary and metastatic
mouse mammary carcinoma with doxorubicin encapsulated in long circulating
liposomes. Int J Cancer 51: 942–948 
Vermorken JB, Kaptein TS, Hart AAM and Pinedo HM (1983) Ototoxicity of
cisdiamminedichloroplatinum (II). Influence of dose, schedule and mode of
administration. Eur J Cancer Clin Oncol 19: 53–58 
Woodle MC and Lasic DD (1992) Sterically stabilized liposomes. Biochem Biophys
Acta 1113: 171 
Phase I study of SPI-77 in paediatric patients 1035
British Journal of Cancer (2001) 84(8), 1029–1035 © 2001 Cancer Research Campaign